Compare FPS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FPS | PRAX |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 7.1B |
| IPO Year | N/A | 2020 |
| Metric | FPS | PRAX |
|---|---|---|
| Price | $59.44 | $263.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $42.63 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 7.0M | 427.5K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $74.33 | N/A |
| Revenue Next Year | $43.11 | $7,758.26 |
| P/E Ratio | $526.99 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.27 | $37.25 |
| 52 Week High | $65.56 | $366.52 |
| Indicator | FPS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 62.35 | 39.24 |
| Support Level | $28.96 | $157.29 |
| Resistance Level | $65.56 | $342.62 |
| Average True Range (ATR) | 4.68 | 21.68 |
| MACD | -0.12 | -6.71 |
| Stochastic Oscillator | 70.69 | 20.77 |
Forgent Power Solutions Inc designs and manufactures electrical distribution equipment for data centers, the power grid, and industrial facilities. Its offerings include automatic transfer switches, transformers (dry type and liquid filled), electrical houses, generator connection cabinets, panelboards, switchboards, switchgear, power distribution units, power skids, remote power panels, and tap boxes.It specializes in manufacturing Custom Products and Powertrain Solutions for technically demanding applications, including data center power distribution, utility substations and energy-intensive manufacturing. The majority of the company's revenue is derived from custom products designed for specific projects with significant engineering consultation.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.